An international study conducted on mice and coordinated by researchers from Inserm, CNRS and Universit Paris-Sud has paved the way towards personalized chronotherapy treatments. In an article published in the journal Cancer Research, the team has shown that the timing of optimal tolerance to irinotecan, a widely used anti-cancer drug, varies by 8 hours depending on the sex and genetic background of mice…
Their report, published in the New England Journal of Medicine, contains further good news. The regular nut-eaters were found to be more slender than those who didn’t eat nuts, a finding that should alleviate the widespread worry that eating a lot of nuts will lead to overweight. …
The study, published on Nov. 19, 2013, in the journal Clinical Cancer Research, adds long-term survival and safety data for the drug tasquinimod, a new candidate for treating advanced and recurrent prostate cancer. “While all subgroups in the clinical trial benefited from tasquinimod, those whose cancer metastasized to their bones had the greatest benefit in terms of delaying the time from the start of treatment to when the cancer progressed,” said lead author Andrew J…
Researchers also found that frail health was associated with a greater risk for adult childhood cancer survivors of death and chronic disease. Being frail was defined by the presence of at least three of the following — weakness, self-reported exhaustion, physical inactivity, low muscle mass and slow walking speed. …
Study Finds Use of Breast MRI in Women Increasing The overall use of breast magnetic resonance imaging has increased, with the procedure most commonly used for diagnostic evaluations and screenings, according to a study published by JAMA Internal Medicine, a JAMA Network publication. While breast MRI is being used increasingly, its sensitivity leads to higher false-positive rates and it is also more expensive…
Investigators in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute have made extensive progress in understanding the molecular mechanisms of disease progression. These results may help scientists better understand the prognosis of patients diagnosed with advanced prostate cancer. The study, published in the journal Cell Cycle and led by Dolores Di Vizio, MD, PhD, may ultimately lead to the development of new biomarkers for not only prognosis, but also a patient’s potential response to therapy. "One of the long-standing difficulties in treating men with advanced prostate cancer has been predicting the response to given therapies or treatments," said Di Vizio, associate professor in the Department of Surgery, Department of Pathology and Laboratory Medicine and Department of Biomedical Sciences. …
Skin tumors — when healing of scratches and cuts goes wrong The skin is the largest organ of the human body, protecting us from dehydration and external impacts. It’s a self-renewing tissue, meaning that if we hurt ourselves for example by scraping or cutting our skin, new skin cells will replace the old damaged ones and our wound will heal. On a molecular level this process is controlled by a wide range of factors, ensuring that the right number of undifferentiated progenitor cells differentiate into skin cells and make their way to replace the old damaged ones. If something goes wrong during this process, pathologies, including skin tumors, can be the consequence…
Preliminary findings of the research were published in the Public Library of Science One Journal by Ratna Ray, Ph.D. associate professor of pathology at Saint Louis University. Ray found that bitter melon extract, a vegetable commonly used in Indian and Chinese diets, reduces the head and neck cancer cell growth in the animal model. "We wanted to see the effect of the bitter melon extract treatment on different types of cancer using different model systems," said Ray, who first tested the extract in breast and prostate cancer cells. …
According to the lead author, Dr. Francesco Atzori, progress in developing new effective drugs in bladder cancer has been stagnant in the last decades. "In patients who recur or who are refractory to first-line therapy, response rates and outcomes are grim, and to date, no second-line therapy has been clearly established," he explained…
A new study from MIT biologists has found that tumor cells with mutated p53 can be made much more vulnerable to chemotherapy by blocking another gene called MK2. In a study of mice, tumors lacking both p53 and MK2 shrank dramatically when treated with the drug cisplatin, while tumors with functional MK2 kept growing after treatment. The findings suggest that giving cancer patients a combination of a DNA-damaging drug and an MK2 inhibitor could be very effective, says Michael Yaffe, the David H. Koch Professor in Science and senior author of a paper describing the research in the Nov…